AASraw inogadzira NMN neNRC powders muhuwandu!

Erlotinib

Rating: Category:

Erlotinib Powder, inotengeswa pasi pezita rekuti Tarceva pakati pevamwe, mushonga unoshandiswa kurapa isiri-diki kenza yemapapu kenza (NSCLC) uye gomarara repancreatic. Kunyanya inoshandiswa iyo NSCLC ine shanduko mune iyo epidermal yekukura factor receptor (EGFR) - ingave exon 19 deletion (del19) kana exon 21 (L858R) inoshandura shanduko - iyo yakapararira kune zvimwe zvikamu zvemuviri.

Product Description

Basic Hunhu

Product Name Erlotinib upfu
CAS Number 183321-74-6
Molecular Formula C22H23N3O4
Formula Weight 393.443
Synonyms CP-358774;

OSI774;

Erlotinib powder isina hwaro;

183321-74-6.

Kuonekwa Yakachena kusvika kune-white crystalline powder
Kuchengeta uye Kubata Kuoma, kusviba uye pa0 - 4 C kwenguva pfupi (mazuva kusvika kumavhiki) kana -20 C kwenguva refu (mwedzi kusvika makore).

 

Erlotinib Powder Tsananguro

Erlotinib powder, inotengeswa pasi pezita rekuti Tarceva pakati pevamwe, mushonga unoshandiswa kurapa isiri-diki kenza yemapapu kenza (NSCLC) uye gomarara repancreatic. Kunyanya inoshandiswa iyo NSCLC ine shanduko mune iyo epidermal yekukura factor receptor (EGFR) - ingave exon 19 deletion (del19) kana exon 21 (L858R) inoshandura shanduko - iyo yakapararira kune zvimwe zvikamu zvemuviri. Inotorwa nemuromo.

Erlotinib powder is quinazoline derivative ine antineoplastic zvimiro. Kukwikwidzana neadenosine triphosphate, erlotinib poda inodzosera ichisunga kune iyo intracellular catalytic domain ye epidermal kukura factor receptor (EGFR) tyrosine kinase, zvichidaro zvichidzora inodzora EGFR phosphorylation uye ichivhara zviitiko zvekutapa kwechiratidzo uye tumorigenic mhedzisiro inosangana neEGFR activation.

Erlotinib powder yakagamuchirwa kuti ishandiswe mune zvekurapa muUnited States muna 2004. Iri paWorld Health Organisation Rondedzero yeMishonga Inokosha, iyo inoronga mishonga yakachengeteka uye inoshanda kwazvo inodiwa muhutano.

 

Erlotinib Powder Maitiro Ekuita

Erlotinib powder ndeye epidermal kukura chinhu receptor inhibitor (EGFR inhibitor). Mushonga unotevera Iressa (gefitinib), waive mushonga wekutanga werudzi urwu.

Erlotinib powder inonyatso tarisa iyo epidermal yekukura factor receptor (EGFR) tyrosine kinase, iyo inoratidzwa zvakanyanya uye dzimwe nguva inoshandurwa munzira dzakasiyana dzekenza. Iyo inosunga mune inodzosera fashoni kune adenosine triphosphate (ATP) inosunga saiti yeiyo inogamuchira. Kuti chiratidzo chiendeswe, mamorekuru maviri eEGFR anofanirwa kuungana kuti aumbe homodimer.

Izvi zvinoshandisa mamorekuru eATP kutapurirana-phosphorylate mumwe neumwe pane tyrosine masara, ayo anogadzira phosphotyrosine masara, kutora mapuroteni e-phosphotyrosine-anosunga kuEGGR kuti aunganidze mapuroteni macomputer ayo anodhindisa chiratidzo anokwenenzverwa kune iyo nucleus kana kumisikidza mamwe maseru emagetsi biochemical maitiro. Kana erlotinib poda ichisunga kuEGFR, kuumbwa kwemaphosphotyrosine masara muEGFR hazviite uye chiratidzo checascades hachina kutangwa.

Erlotinib powder zvakare ndeye tyrosine kinase receptor inhibitor iyo inoshandiswa pakurapa kwepamberi kana metastatic pancreatic kana isiri-diki kenza yemapapu yemukenza. Erlotinib poda yekurapa inosanganisirwa nekukwirisa kwenguva pfupi mumaseru emaminotransferase panguva yekurapa uye zvisingawanzo zviitiko zvekurapa zvinoita sekukuvara kwechiropa kwakanyanya.

 

Erlotinib Powder Chikumbiro 

Erlotinib powder ndeye inodzoserwa yekutanga-chizvarwa receptor tyrosine kinase inhibitor (pamwe naGefitinib) inoshanda zvakanyanya pane epidermal kukura factor receptor (EGFR), nhengo yemhuri yeErbB yekugamuchira. Iyo mishonga inopindirana neese emusango mhando uye shanduko EGFR. Mhuri yeErbB inogona kuumba mahemodimers kana maheterodimers, ayo anowanzo kuverengerwa mukudzikira kwemhedzisiro uye pathogenesis yemhando dzakawanda dzekarcinoma dzakadzidza muvanhu. Receptor tyrosine kinase inhibitors (TKI) inodzivirira iyo phosphorylation yeiyo substrate yavo muchitokisi inoratidzira nzira. EGFR inowanzoita basa mune akawanda maseru mashandiro, kusanganisira kusiyanisa, kuwanda, uye angiogenesis, ese ayo anozivikanwa ekenza.

EGFR shanduko muNSCLC inowanzo shandura shanduko. Humwe murwere hunhu hunoita kuti kuvepo kweEGFR shanduko ingango sanganisira hapana nhoroondo yekusvuta yakasimbisa adenocarcinoma ne histologic ongororo, dzinza reAsia, uye mukadzi pabonde. Shanduko dzechipiri muEGFR dzinowanzoitika, idzo inotsanangurwa nechinyorwa chino pazasi.

 

Erlotinib Powder Side Mhedzisiro & Yambiro

Iyi inotevera mhedzisiro yakajairika kune varwere vanotora Erlotinib Powder:

▪ Mapundu

▪ Manyoka

▪ Kusadya zvakanaka

▪ Kuneta

▪ Kufema kwenguva pfupi

▪ Kukosora

▪ kusvotwa uye kurutsa

 

Iyi mhedzisiro haina kujairika mhedzisiro yevarwere vanowana Erlotinib Powder:

▪ Kutapukirwa

▪ Maronda emumuromo

▪ Kuvava

▪ Ganda rakaoma

▪ Kushatirwa mumaziso

▪ Kurwadziwa mudumbu

 

Haasi ese mhedzisiro akanyorwa pamusoro. Zvimwe izvo zvisingawanzoitika (zvinoitika mune isingasviki gumi muzana yevarwere) hazvina kunyorwa pano. Nekudaro, iwe unofanirwa kugara uchizivisa mupi wako wezvehutano kana iwe uchinge uchinge uchinge uchinge uchinge uchinge uchinge uchinge uchinge uchinge uchiona zviratidzo

 

Reference

[1] Gao JW, Zhan P, Qiu XY, Jin JJ, Lv TF, Rwiyo Y. Erlotinib-based doublet yakanangwa kurapwa kurwisa erlotinib poda yega mune yakamborapwa yakasimukira isiri-diki-sero kenza yemapapu: meta-ongororo kubva ku24 yakasarudzika. kudzorwa miedzo. Oncotarget. 2017 Chivabvu 31; 8 (42): 73258-73270. doi: 10.18632 / oncotarget.18319. eCollection 2017 Sep 22. Ongororo. PubMed PMID: 29069867; PubMed Central PMCID: PMC5641210.

[2] Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Ishe S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T , Yang JC. Gefitinib kana Erlotinib powder vs Chemotherapy yeEGFR Mutation-Yakanaka Lung Cancer: Mumwe Nomumwe Murwere Dhata Meta-Kuongorora kweKupona Kwese. J Natl Cancer Inst. 2017 Jun 1; 109 (6). doi: 10.1093 / jnci / djw279. Ongorora. PubMed PMID: 28376144.

[3] Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Kuenzaniswa kwegefitinib, erlotinib powder uye afatinib mune isiri-diki kenza yemapapu kenza: Meta-ongororo. Int J Kenza. 2017 Jun 15; 140 (12): 2805-2819. doi: 10.1002 / ijc.30691. Epub 2017 Mar 27. Ongororo. PubMed PMID: 28295308.

[4] "Erlotinib powder (Tarceva) Shandisa Panguva Yepamuviri". Zvinodhaka.com. 1 Mbudzi 2019. Yakadzorerwa 23 Zvita 2019.

[5] "Erlotinib powder Monograph yeVashandi". Zvinodhaka.com. Yakadzorerwa 12 Mbudzi 2019.

[6] "Tarceva- erlotinib powder hydrochloride piritsi". Zuva Nezuva. 12 Zvita 2018. Yakadzorerwa 23 Zvita 2019.

[7] "Kubvumidzwa Kwemishonga Package: Tarceva (Erlotinib powder) NDA # 021743". US Kudya neDrug Administration (FDA). 28 Kurume 2005. Yakadzorerwa 23 Zvita 2019.

[8] Raymond E, Faivre S, Armand JP (2000). "Epidermal kukura chinhu receptor tyrosine kinase sechinangwa cheanticancer therapy". Zvinodhaka. 60 Suppl 1: 15-23, hurukuro 41–2. doi: 10.2165 / 00003495-200060001-00002. PMID 11129168. S2CID 10555942.